PURE Bioscience to Host Year End Results Conference Call October 24, 2013
2013年10月22日 - 9:30PM
Marketwired
PURE Bioscience to Host Year End Results Conference Call October
24, 2013
New Management Team Discussion of Refocused Business
Strategy
SAN DIEGO, CA--(Marketwired - Oct 22, 2013) - PURE Bioscience,
Inc. (OTCQB: PURE), creator of the patented silver dihydrogen
citrate (SDC) antimicrobial, today announced that the Company will
host an investor conference call on Thursday, October 24, 2013 at
2:00 PM Pacific Time (5:00 pm Eastern Time). In addition to
reviewing fiscal year end 2013 financial results, the purpose of
this call is to:
- Introduce the new management team,
- Outline the Company's refocused business strategy in the food
safety arena, and
- Discuss steps being taken to restore PURE's financial
condition.
PURE intends to file its Form 10-K on the October 24th after the
close of the stock market.
The Participant Dial-In Number for the conference call is
1-412-902-6720. Participants should dial in to the call at least
five minutes before 2:00 pm PDT (5:00 pm EDT) on October 24, 2013.
The call can also be accessed "live" online at
http://public.viavid.com/index.php?id=106520.
A replay of the webcast will be available at
http://public.viavid.com/index.php?id=106520 as well as on the
Company's website (www.purebio.com). Also, a replay of the
conference call will be available by dialing 1-877-870-5176
(international participants dial 1-858-384-5517) starting October
24, 2013, at 8:00 PM Eastern Time through December 8, 2013 at 11:59
pm Eastern Time. Please use PIN Number 91024.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and
commercializing our proprietary antimicrobial products that provide
solutions to the health and environmental challenges of pathogen
and hygienic control. Our technology platform is based on patented
stabilized ionic silver, and our initial products contain silver
dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic
antimicrobial agent, which offers 24-hour residual protection and
formulates well with other compounds. As a platform technology, SDC
is distinguished from competitors in the marketplace because of its
superior efficacy, reduced toxicity and the inability of bacteria
to form a resistance to it. PURE is headquartered in El Cajon,
California (San Diego metropolitan area). Additional information on
PURE is available at www.purebio.com.
Forward-looking Statements
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe," "estimate," "expect," "intend," "project" or similar
expressions. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's cash position and liquidity requirements, the Company's
failure to implement or otherwise achieve the benefits of its
proposed business initiatives and plans, acceptance of the
Company's current and future products and services in the
marketplace, the ability of the Company to develop effective new
products and receive regulatory approvals of such products,
competitive factors, dependence upon third-party vendors, and other
risks detailed in the Company's periodic report filings with the
Securities and Exchange Commission. You should not place undue
reliance on these forward-looking statements. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release.
Contact: IR Contacts: Tom Hemingway Redwood Investment Group
714-978-4425 Email Contact Terri MacInnis, Director of IR Bibicoff
+ MacInnis, Inc. 818-379-8500 Email Contact Company Contact: Peter
C. Wulff, CFO & COO PURE Bioscience, Inc. 619-596-8600 ext.111
Email Contact
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 6 2024 まで 7 2024
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 7 2023 まで 7 2024